Compare CBUS & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBUS | NSPR |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.9M | 67.4M |
| IPO Year | 2017 | N/A |
| Metric | CBUS | NSPR |
|---|---|---|
| Price | $1.57 | $1.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $20.00 | $4.00 |
| AVG Volume (30 Days) | ★ 299.6K | 44.5K |
| Earning Date | 11-13-2025 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,794,000.00 | ★ $7,779,000.00 |
| Revenue This Year | N/A | $22.76 |
| Revenue Next Year | $109.96 | $75.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.04 |
| 52 Week Low | $1.09 | $1.51 |
| 52 Week High | $3.40 | $3.80 |
| Indicator | CBUS | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 42.46 |
| Support Level | $1.46 | $1.53 |
| Resistance Level | $2.04 | $1.74 |
| Average True Range (ATR) | 0.25 | 0.14 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 9.82 | 38.64 |
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.